Clostridium difficile is well-known as the primary etiological agent of antibiotic-associated colitis (1, 5) . Although most reported cases have been related to treatment with clindamycin, lincomycin, ampicillin, or the cephalosporins, almost all other antibacterial agents have been implicated.
The quinolones are a promising group of antimicrobial agents with a broad spectrum of activity. Recently, several new compounds have been widely investigated. In vitro studies have shown that they have excellent activity against aerobic bacteria (11) and relatively poor activity against anaerobic bacteria (6, 10) . The relatively low levels of drug in serum that have been obtained are compensated by very low MICs. Although no cases of antibiotic-associated colitis have been reported after treatment with these compounds so far, the potential of inducing colitis must be considered for other broad-spectrum antimicrobial agents such as cephalosporins.
We studied the activity of seven quinolone derivatives against 100 clinical isolates of C. difficile obtained from different sources.
The 100 C. difficile strains tested were selected from our collection. All isolates were identified by gas chromatographic and classical biochemical procedures (8) incubated anaerobically at 37°C in Gas-Pak jars. The inoculum per spot was 105 CFU. Table 1 gives the MICs at which 50 and 90% of the strains were inhibited by each antimicrobial agent. The range was narrow in all cases. Nalidixic acid, norfloxacin, pefloxacin, and enoxacin showed uniformly poor activity against all strains tested. Ofloxacin and ciprofloxacin showed moderate activity. C1934 was the most active compound tested, inhibiting 90% of the strains at 4 ,ug/ml and 100% at 8 ,ug/ml. Although strains originated from very different sources, there was no correlation between susceptibility and origin, serogroup, or toxigenicity.
The MICs for ciprofloxacin and norfloxacin were somewhat higher than those obtained by Goodman et al. (7) and Sutter et al (10) . The use of an inoculum of 105 organisms instead of 104 could explain this difference.
Ofloxacin, ciprofloxacin, and particularly C1934 appeared to be more active against C. difficile than the other new quinolones. These results suggest that there may be a lower risk to induced colitis after treatment with these drugs. However, only limited data are available about the levels of the new quinolones in feces during therapy. Recently, it was reported (2) that norfloxacin maintains levels of >50 ,ug/g of feces for 24 h and achieve peak levels of >290 ,ug/ml after a single oral 400-mg dose. At these levels, all of our strains were inhibited by norfloxacin. However, it is known that, in cases of antibiotic-associated colitis, some strains of C. difficile are relatively susceptible to the antimicrobial agent implicated in causing the disease (4) . Spores are insensitive to antimicrobial agents. Consequently, the main factor inducing colitis may be an alteration of the normal bowel flora. From this point of view, new quinolones that have a broad spectrum of activity could, like the cephalosporins, present a risk of induced colitis.The most active compounds against 
